Table 2.
Pathological and oncological outcomes in men received LRP or RARP.
| LRP (n = 250) | RARP (n = 450) | Pvalue | ||
|---|---|---|---|---|
| Gleason score (%) | 6 | 71 (28.4) | 132 (29.3) | 0.173 |
| 7 | 147 (58.8) | 238 (52.9) | ||
| 8–10 | 32 (12.8) | 80 (17.8) | ||
| Pathological T stage (%) | 0 | 0 (0) | 1 (0.2) | N.A. |
| 2a | 27 (10.8) | 41 (9.1) | 0.276 | |
| 2b | 42 (16.8) | 69 (18.3) | 0.342 | |
| 2c | 120 (48.0) | 201 (44.7) | 0.396 | |
| 3a | 45 (18.0) | 111 (24.7) | 0.025 | |
| 3b | 14 (5.6) | 26 (5.8) | 0.535 | |
| 4 | 2 (0.8) | 1 (0.1) | 0.293 | |
| Lymphovascular invasion (%) | 0 | 182 (72.8) | 272 (60.4) | 0.001 |
| 1 | 68 (27.2) | 178 (49.6) | ||
| Perineural invasion | 0 | 102 (40.8) | 130 (28.9) | 0.001 |
| 1 | 148 (59.2) | 320 (71.1) | ||
| N stage (%) | 0 | 246 (98.4) | 419 (93.1) | 0.002 |
| Positive surgical margin (%) | Total | 78 (31.2) | 93 (20.7) | 0.002 |
| BCR (%) | 53 (21.2) | 46 (10.2) | <0.0001 | |
| Salvage therapy | RT | 3 | 16 | |
| ADT | 16 | 14 | ||
| RT + ADT | 9 | 12 | ||
| Surveillance | 0 | 0 | ||
LRP, laparoscopic radical prostatectomy; RARP, robot-assisted radical prostatectomy; BCR, biochemical recurrence; RT, radiation therapy; ADT, androgen deprivation therapy.